Blonanserin
Atypical antipsychotic / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about blonanserin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic (approved by PMDA in January 2008)[2] commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia.[3] Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.[4] As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.[5]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Lonasen |
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 55%[1] |
Metabolism | CYP3A4[1] |
Elimination half-life | 12 h[1] |
Excretion | 59% (urine), 30% (faeces)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.211.656 |
Chemical and physical data | |
Formula | C23H30FN3 |
Molar mass | 367.512 g·mol−1 |
3D model (JSmol) | |
|
Close